GO
Loading...

Novartis AG

More

  • Your Health, Your Trade Wednesday, 10 Oct 2007 | 11:01 PM ET

    BREAKING: Reuters reports FDA panel backs drug-coated stents made by Medtronic (MDT).

  • Novartis Says Prexige Not Approved in U.S. Thursday, 27 Sep 2007 | 9:16 AM ET

    U.S. regulators have not approved Novartis's Prexige painkiller, the Swiss drugmaker said on Thursday, in an expected move after Australia withdrew the drug due to concerns over liver side effects.

  • EU Approves of Novartis' Exelon to Treat Alzheimer's Monday, 24 Sep 2007 | 9:21 AM ET

    The drugmaker Novartis said Monday that the European Commission had approved its Exelon skin patch to treat Alzheimer's disease.

  • Novartis Bone Drug Curbs Repeat Hip Fractures Monday, 17 Sep 2007 | 11:54 PM ET

    In a study that could change the way hip fractures are treated, doctors have discovered that giving the Novartis osteoporosis drug Reclast can prevent later fractures and helps patients live longer.

  • Roche Sues Teva in U.S. Over Bone Drug Tuesday, 11 Sep 2007 | 5:08 AM ET

    Swiss drugmaker Roche Holding is taking legal action against Israel's Teva Pharmaceutical Industries in the United States to prevent Teva from selling a generic version of Roche osteoporisis drug Boniva, Roche said on Tuesday.

  • It's Time for the Lightning Round! Monday, 27 Aug 2007 | 7:31 PM ET

    American Standard, Dell, Southern Copper and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Drug Downers Thursday, 16 Aug 2007 | 3:58 PM ET
    Elvis Presley

    Thirty years ago, I was in Las Vegas. My stepmother took me to see Ann-Margret at The Hilton and I remember our waitress telling us that Elvis was the only one who could consistently pack the room. It was strange that he passed away the next day. On this, the 30th anniversary of the King's death from overdosing on prescription drugs, the stocks of the companies that make prescription drugs are having a very dark day.

  • Riding The Rally Tuesday, 31 Jul 2007 | 11:06 AM ET

    With stocks in rally mode, it's appropriate to drill down for answers as well as take a look at some key sectors.

  • Roche Holding said Thursday its CEO will step down next March as the pharmaceutical company separates that job from the chairman's position. It also posted a 24% increase in first-half net profit.

  • Novartis cut its full-year results outlook as generic competition pressured sales of a key blood-pressure drug, and said U.S. regulators had delayed the approval process for an important cancer treatment.

  • Nestle to Cut Plants, Products as Prices Soar Thursday, 12 Jul 2007 | 8:03 AM ET

    Nestle, the world's largest food company, will raise prices, cull unprofitable products and speed up production rationalization to prepare for a lasting rise in commodity and energy prices.

  • Roche has signed a deal worth up to $1 billion with Alnylam Pharmaceuticals, giving it access to the U.S. firm's skills in the new science of silencing genes to fight disease.

  • Novartis Gets EU OK for New Flu Vaccine Wednesday, 13 Jun 2007 | 4:25 AM ET

    Swiss drugmaker Novartis said Wednesday it has received European Union approval for flu vaccine Optaflu.

  • Buying Big Pharma - If You Must Tuesday, 12 Jun 2007 | 7:03 PM ET

    It’s slim pickings in the sector, but there are a couple of stocks that are actually worth buying, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Big Pharma Is Bad Investing Tuesday, 12 Jun 2007 | 7:00 PM ET

    Without patents or pipeline, drug companies just don't have the growth investors crave anymore. Cramer tells you who to avoid.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • ASCO: The Super Bowl Of Science Friday, 1 Jun 2007 | 1:41 PM ET

    What’s the biggest event of the year for biotech and big pharma? It’s the 43rd ASCO Annual Meeting where drug companies present new research that could indicate whether their cancer drugs are blockbusters or duds. It starts this Friday night in Chicago - what should you expect?

  • Severe kidney failure and some deaths have been reported in patients using Novartis's iron overload drug Exjade, the Food and Drug Administration said.

  • Health Care Stocks Look in The Pink, Says Strategist Monday, 21 May 2007 | 11:53 AM ET

    The market may see a Democratic congress (and possibly the White House in 2008) as detrimental to health care stocks -- but Henssler Financial Group's Ted Parrish begs to disagree. Parrish, the co-portfolio manager of the firm's Henssler Equity Fund joined "Squawk on the Street" to tout the opportunities in health care companies -- and name his favorites.

  • Pharmaceuticals a Good Bet, Analysts Say Tuesday, 8 May 2007 | 1:10 PM ET

    Michael Krensavage, pharmaceutical analyst at Raymond James, told CNBC’s “Morning Call” that strong revenue and earnings growth will reward investors in the pharmaceutical sector.

  • A new study offers the millions of people who have osteoporosis the hope of taking a drug to treat it only once a year. The New England Journal of Medicine reports that patients who got a once-a-year infusion of the Novartis drug Reclast saw a 70% reduction in the risk of spinal fractures and a 40% drop in the risk of hip fractures.

Most Popular Video

Thursday, 17 Apr 2014 | 9:01 AM ET

The "Squawk on the Street" news team break down some blue chip earnings, including Goldman Sachs, Morgan Stanley and American Express.

Thursday, 17 Apr 2014 | 9:52 AM ET

CNBC's Allison Linn reports on new research that shows how employees who do something creative after work—like knitting, drawing or even playing a creative video game—are more likely to be helpful and creative problem solvers on the job.

Thursday, 17 Apr 2014 | 9:04 AM ET

CNBC's Jim Cramer breaks down General Electric's quarterly results and reveals the 2 big growth areas he sees in the economy.